According to a new study, single-tablet regimens may provide better virologic response and control than multiple-tablet regimens for people living with HIV, likely due to a lower pill burden and, ...
Results from ARTISTRY trials will be submitted to regulatory agencies for review. Topline results were announced from a phase 3 trial evaluating bictegravir 75mg/lenacapavir 50mg (BIC/LEN), an ...
– Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis of Regulatory Submissions – FOSTER CITY, Calif., November 13, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today ...
A new study from UC San Francisco shows it may be possible to control HIV without long-term antiviral treatment — an advance that points the way toward a possible cure for a disease that affects 40 ...
The FDA has approved Tivicay PD (dolutegravir; Viiv Healthcare) tablets for oral suspension, for the treatment of HIV-1 infection in treatment-naïve or -experienced but integrase inhibitor-naïve ...
Measuring HIV replication control: not enough in African populations The degree of viral infection is measured by the virus' "setpoint viral load " (spVL), which refers to the relatively stable level ...
– The Novel HIV Therapy has the Potential to Expand Options for Virologically Suppressed Adults Treated with Complex ART Regimens – – Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis ...
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment responses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback